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The transmembrane protein ADAM22 is expressed at high levels in the brain. From its molecular structure, 
ADAM22 is thought to be an adhesion molecule or a receptor because it has functional disintegrin-like and cys-
teine-rich sequences in its ectodomain. The phenotypic analysis of ADAM22-deficient mice has indicated the 
important roles played by ADAM22 in proper neuronal function and peripheral nerve development, however, 
the precise molecular function of ADAM22 is still unknown. To understand the function of ADAM22 on a mo-
lecular basis, we identified ADAM22 binding proteins by using immunoprecipitation and mass spectrometric 
analysis. This analysis revealed that Leucine-rich glioma inactivated 1 (LGI1) is the most potent ADAM22 bind-
ing protein in mouse brain. By our quantitative cell-ELISA system, we demonstrated the specific binding of LGI1 
with ADAM22. Furthermore, we showed that LGI4, a putative ADAM22 ligand, also bound to ADAM22. Char-
acterization of the binding specificity of LGI1 and LGI4 suggested that ADAM22 is not a sole receptor, because 
ADAM11 and ADAM23 had a significant binding ability to LGI1 or LGI4. Therefore, LGI-ADAM system seems 
to be regulated not only by the affinity but also by the cell-type-specific expression of each protein. Our findings 
provide new clues to understand the functions of LGI1 and LGI4 as an ADAMs ligand. 
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INTRODUCTION 
A Disintegrin And Metalloprotease (ADAM) is a 
family of membrane-spanning multi-domain proteins 
containing a metalloproteinase-like domain and a 
disintegrin-like domain. Already, more than 30 AD-
AMs have been identified in mammals. Some types of 
ADAM are catalytically active metalloproteases and 
they control receptor-mediated signals by activating 
membrane-bound growth factors or by shedding the 
ectodomain of cell-surface receptors [1,2]. ADAMs are 
also involved in cell-cell or cell-matrix adhesion 
through their interaction with integrins or syndecans. 
More than 10 ADAMs have been shown to support 
integrin-mediated cell adhesion in vitro [3]. An analy-
sis of knockout mice has revealed the physiological 
roles of ADAM family proteins in fertilization, myo-
genesis and neurogenesis [4,5]. 
We have reported our findings on ADAM11, 
ADAM22 and ADAM23 genes and their restricted 
expression in the nervous system [6,7]. Sequence 
analysis suggests that they are not metalloproteases, 
since they all lack a catalytic motif. Recently, we re-
vealed that ADAM11 is essential for a proper neuronal 
function because ADAM11-deficient mice showed 
deficits in special learning, motor coordination and 
nociceptive response [8,9]. Furthermore, we have re-
ported that mice with a truncated mutation of 
ADAM22 exhibited ataxia, seizure and hypomyelina-
tion in the peripheral nerves [10]. It has been reported 
that the disruption of the Adam23 gene in mice results 
in premature death associated with ataxia and tremor 
[11]. These findings indicate that these three ADAMs 
are non-redundant and have distinct functions.   
In this study, we identified LGI1 as a specific 
binding partner of ADAM22 protein from mouse 
brain, and demonstrated the specific interaction be-
tween LGI1 and ADAM22 by employing a quantita-
tive cell-ELISA assay. We also showed that LGI4 binds 
to ADAM22 as well. In addition, characterization of 
the binding specificity of LGI1 and LGI4 revealed that 
ADAM22 is not a sole receptor for them. Our results 
suggest that LGI-ADAM system is more complicated 
than initially thought. Int. J. Biol. Sci. 2008, 4 
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MATERIALS AND METHODS 
Experimental Animals 
All the animal procedures conformed to Japanese 
regulations on the care and use of animals. Moreover, 
the procedures were in accordance with the Guideline 
for Animal Experimentation of the Japanese Associa-
tion for Laboratory Animal Science, and were ap-
proved by the Animal Care and Use Committee of 
Eisai Co., Ltd. Male C57/BL6 mice were purchased 
from Charles River Japan (Tokyo, Japan).   
Antibodies 
The rabbit anti-ADAM22-cyto polyclonal anti-
body was created in our laboratory [10]. The 
anti-FLAG-M2 mouse monoclonal antibody and 
anti-HA11 mouse monoclonal antibody were pur-
chased from SIGMA (MO, USA) and Covance (NJ, 
USA), respectively.   
Immunoprecipitation 
C57/BL6 mice were sacrificed and their whole 
brains were quickly removed, frozen in liquid nitro-
gen, and stored at -80 °C. Each mouse brain was ho-
mogenated with a Polytron homogenizer in 5 ml of 
TN buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 
% NP-40) containing protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). To remove debris, 
the homogenates were centrifuged at 15,000g for 5 
min, and the resulting supernatants were cleared by 
0.45 μm filtration. Anti-ADAM22-cyto antibody (4 μg) 
were added to 1.6 ml of cleared brain homogenate and 
incubated for 60 min at room temperature, followed 
by incubation with 100 μl of Protein-G Agarose (Roche 
Diagnostics, Mannheim, Germany). The agarose beads 
were washed three times with TN buffer, and then the 
bound proteins were eluted in 100 μl of 1.25x 
SDS-PAGE sample buffer at 95 °C. As a negative con-
trol, rabbit normal IgG was used instead of 
anti-ADAM22-cyto antibody.   
Immunoblot and Silver Stain Analysis 
The samples were separated on 10 % SDS-PAGE, 
and transferred to a nitrocellulose membrane. The blot 
was then incubated with anti-ADAM22-cyto antibody 
(0.4  μl/ml), and visualized with HRP-conjugated 
anti-rabbit IgG and an ECL-Plus chemiluminescence 
detection system (GE Healthcare, NJ, USA). Silver 
staining was performed using Silver Stain Kit (Daiichi 
Pure Chemicals, Tokyo, Japan) according to the 
manufacturer’s instructions.   
Protein Identification of 60 kDa Gel Band by Mass 
Spectrometry 
The target gel band at 60 kDa and the corre-
sponding band of the negative control were excised 
after silver staining. In-gel digestion was performed in 
the presence of Cymal-5 according to the protocol de-
scribed by Katayama et al. [24]. After being desalted 
using StageTips [25], each sample was analyzed with a 
nanoLC-MS system consisting of a Finnigan LTQ mass 
spectrometer (Thermo Fisher Scientific, Bremen, Ger-
many), a Dionex Ultimate3000 pump with an 
FLM-3000 flow manager (Germering, Germany) and 
an HTC-PAL autosampler (CTC Analytics, Zwingen, 
Switzerland). ReproSil-Pur C18 materials (3 μm, Dr. 
Maisch, Ammerbuch, Germany) were packed into a 
self-pulled needle (150 mm length x 100 μm I.D., 6 μm 
opening) to prepare an analytical column needle [26] 
The injection volume was 5 μL and the flow rate was 
500 nL/min. The mobile phases consisted of (A) 0.5 % 
acetic acid and (B) 0.5 % acetic acid and 80 % acetoni-
trile. A two-step linear gradient of 5 % to 30 % B in 15 
min, 30 % to 100 % B in 5 min and 100 % B for 10 min 
was used. A spray voltage of 2400 V was applied. The 
MS scan range was m/z 300-1500 and the top ten 
precursor ions were selected for subsequent MS/MS 
scans. A Mass Navigator v1.2 (Mitsui Knowledge In-
dustry, Tokyo, Japan) was used to create peak lists on 
the basis of the recorded fragmentation spectra. Pep-
tides and proteins were identified by Mascot v2.1 
(Matrix Science, London) against UniProt/SwissProt 
v54.0 with a precursor mass tolerance of 2.0 Da, a 
fragment ion mass tolerance of 0.8 Da, rodent taxon-
omy, and strict trypsin specificity allowing for up to 1 
missed cleavage. The carbamidomethylation of cys-
teine was set as a fixed modification, and methionine 
oxidation was allowed as a variable modification. 
Peptides were considered identified if the Mascot 
score was over the 95 % confidence limit based on the 
‘identity’ score of each peptide, and at least two pep-
tides per protein were observed for protein identifica-
tion. The protein content was calculated based on the 
emPAI values [13]. Briefly, the number of observed 
precursor ions per protein was normalized by the 
number of observable peptides per protein. Then, 
these normalized values were converted to exponen-
tial values so that they were proportional to the pro-
tein abundance. The emPAI calculation was per-
formed automatically using a script called emPAI Calc 
(http://empai.iab.keio.ac.jp/).  
Affinity Purification of mouse ADAM22 complex 
The ADAM22-matrix was constructed by cou-
pling 50 μg of anti-ADAM22-cyto antibody with 500 
μl of AminoLink gel (PIERCE, IL, USA) according to 
the manufacturer’s instructions. In the same way, 
normal rabbit IgG was used to construct the Nega-
tive-matrix. Brain homogenates obtained from 
one-third of a single brain were incubated with 55 μg Int. J. Biol. Sci. 2008, 4 
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of ADAM22-matrix or Negative-matrix for 60 min at 
room temperature. The matrixes were washed three 
times in TN buffer, then the bound proteins were 
eluted in 60 μl of 2x SDS-PAGE sample buffer at 95 °C. 
To obtain the final test samples with a 1x SDS concen-
tration, the eluted samples were diluted with an equal 
amount of distilled water. These test samples were 
then subjected to immunoblot analysis, silver staining 
and GeLC-MS analysis.   
GeLC-MS Analysis 
After separation by SDS-PAGE (5-20 %, 0.5 mm 
thickness), entire lanes were cut out, sliced into 4 
pieces, digested and desalted as described above. Each 
slice was analyzed with nanoLC-MS as described ear-
lier except for the gradient condition where 5 % to 10 
% B in 5 min, 10 % to 30 % B in 60 min, 30 % to 100 % 
B in 5 min and 100 % B for 10 min were used. The 
Mascot database searching against UniProt/SwissProt 
v54.0 was done for each sample and the obtained re-
sults were merged to allow a comparison of the 
ADAM22-immunoprecipitated sample and the nega-
tive control. The emPAI Calc script was used to esti-
mate protein abundance.   
Plasmid Construction 
3.1M-mADAM22: Mouse ADAM22-A04 (al-
pha-form) cDNA was subcloned into the 
pcDNA3.1-vector (Invitrogen, CA, USA). 
3.1M-hAD11-FG, 3.1M-hAD22a-FG, 3.1M-hAD23-FG: 
The cDNAs encoding human ADAM11, 
ADAM22-alpha, ADAM23 tagged with the FLAG 
epitope (DYKDDDDK) at the C-terminus were sub-
cloned into the pcDNA3.1-vector. 3.1M-mLGI1-HA, 
3.1M-mLGI4-HA: Mouse LGI1 and LGI4 cDNAs were 
amplified from mouse brain Quick-Clone cDNA 
(Clontech, CA, USA) with a FastStart High Fidelity 
PCR System (Roche Diagnostics, Mannheim, Ger-
many). The amplified DNA fragments were cloned 
into the pT7Blue-vector (Novagen, WI, USA). After 
sequence verification, each cDNA was tagged with the 
HA epitope (YPYDVPDYA) at the C-terminus, and 
subcloned into the pcDNA3.1-vector. 
Cell-based ELISA 
HeLa cells were cultured in RPMI-1640 medium 
with 10 % calf serum, and plated onto a 96-well cell 
culture plate one day before transfection. Two plas-
mids (0.1 μg each) were mixed and cotransfected to 
the HeLa cells using Lipofectamine2000 reagent (Invi-
trogen, CA, USA). After a 48 hr incubation, the cells 
were washed twice with D-PBS (SIGMA, MO, USA), 
and fixed in 4 % paraformaldehyde (Wako Pure 
Chemicals, Osaka, Japan) for 15 min. To detect cell 
surface HA-epitope, the cells were immediately trans-
ferred to the blocking step without permeabilization. 
Instead, when detecting the total amount of 
FLAG-epitope, the cells were permeabilized with 0.1 
% TritonX-100 for 15 min, followed by blocking. 
Blocking was performed using 1x Blockace solution 
(Dainippon Pharmaceutical, Osaka, Japan) for 30 min 
at room temperature. The cells were incubated with 
primary antibodies (anti-HA; 1:500 dilution, 
anti-FLAG; 1:1000 dilution) for 30 min, and then 
washed three times with TBST (50 mM Tris-HCl pH 
7.4, 500 mM NaCl, 0.05 % Tween20). After being 
washed, the cells were incubated with 
HRP-conjugated sheep anti-mouse-IgG antibody (GE 
Healthcare, NJ, USA) in a 1:1000 dilution for 30 min 
and then washed three times. The cell-bound secon-
dary antibodies were detected using TMB substrate 
solution (KPL, MD, USA). The colorimetric reaction 
was stopped by the addition of the TMB Stop solution 
(KPL, MD, USA) and the resulting plates were meas-
ured at 450 nm absorption with a SUNRISE microplate 
reader (Tecan Japan, Kanagawa, Japan).   
RESULTS 
Isolation of ADAM22 binding proteins from mouse 
brain 
To isolate ADAM22 binding proteins from 
mouse brain, we performed immunoprecipitation ex-
periments using anti-ADAM22-cyto antibody, which 
recognizes the cytoplasmic region of human and 
mouse ADAM22 protein. First, the immunoprecipi-
tates of anti-ADAM22-cyto antibody from mouse 
whole brain were examined by immunoblot analysis. 
As shown in Figure 1A, ADAM22 proteins were 
highly concentrated by this immunoprecipitation (lane 
3). On the other hand, no ADAM22 protein was de-
tected in the immunoprecipitates of normal rabbit an-
tibody (lane 5). ADAM22 proteins were observed as 
multiple bands with molecular weights of 70 to 90 
kDa. These multiple bands are thought to be proteins 
translated from splicing variants, because a wide vari-
ety of ADAM22-transcripts have been reported in 
mice [10,12]. Second, the protein composition of 
ADAM22-immunoprecipitates (sample #3) and nega-
tive-IP-control (sample #5) were analyzed by silver 
staining (Figure 1B). A strong band with a molecular 
weight of approximately 60 kDa (arrow in Figure 1B) 
was observed in the ADAM22-immunoprecipitates 
but not in the negative control, suggesting that this 
60-kDa protein is a specific binder of ADAM22. Mass 
spectrometry analysis revealed that the most abun-
dant protein (68.7 %) in this 60 kDa band was Leu-
cine-rich glioma inactivated-1 (LGI1) based on the 
emPAI score, which is derived from the number of 
observed peptides per protein and is proportional to Int. J. Biol. Sci. 2008, 4 
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protein abundance [13]. The predicted molecular 
weight of mouse LGI1 is approx 63 kDa, which is con-
sistent with the mobility in our SDS-PAGE analysis. 
 
 
Figure 1. Immunoprecipitation of ADAM22 from mouse brain. A) Immunoblot analysis. Each sample was examined by im-
munoblot analysis using anti-ADAM22-cyto antibody. B) Silver stain analysis. Immunoprecipitates of ADAM22-cyto (#3) and 
control IgG (#5) were examined by silver stain analysis. ADAM22 proteins are indicated by arrowheads and the 60-kDa specific 
band is indicated by an arrow. C) Mass spectrometric analysis. Protein list of the identified proteins in 60 kDa band of 
ADAM22-immunoprecipitates. *Content (%) was calculated using emPAI values. D) Identified peptides assigned mouse LGI1. 
PeptScore is the Mascot peptide score for each peptide in identification. 
GeLC-MS analysis of ADAM22-IP-complex 
Comparative GeLC-MS analysis [14] is a good 
way to obtain information about the composition pro-
file of a protein complex. However, when we used 
immobilized protein-G and primary antibody for the 
purification, a large amount of IgG coeluted in the 
immunoprecipitate sample sometimes prevents effec-
tive protein detection. To overcome this problem, we 
made two types of affinity matrixes, which were co-
valently linked by rabbit anti-ADAM22-cyto antibody 
(ADAM22-matrix) or control rabbit IgG (nega-
tive-matrix), respectively. Both matrixes were incu-
bated with cleared homogenate obtained from mouse 
whole brain, washed thoroughly and eluted with a 
solution containing denaturing agents. As shown in 
Figure 2A, effective purification of ADAM22-complex 
was accomplished by using the ADAM22-matrix. Fig-
ure 2B indicates the decrease in the amount of IgG in 
sample #7 with keeping the 60 kDa-binding protein 
(arrow). We performed GeLC-MS analysis and identi-
fied 133 and 162 proteins for samples #7 and #9, re-
spectively. Table 1 shows 133 proteins identified from 
the ADAM22-matrix, and these proteins are plotted by 
the number of identified peptides for the Int. J. Biol. Sci. 2008, 4 
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ADAM22-matrix and the negative-matrix (Figure 2C). 
This graph clearly shows that ADAM22 and LGI1 
were specifically bound to the ADAM22-matrix 
among the 133 proteins.   
Table 1. Comparative GeLC-MS analysis. 133 proteins identified for sample #7 (ADAM22-matrix bound proteins) were arranged 
according to the numbers of unique peptides observed with GeLC-MS analysis. For each protein, the numbers of observed peptides 
for sample #9 (negative-matrix bound proteins) are also indicated. 
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Figure 2. Comparative GeLC-MS analysis for ADAM22-matrix bound proteins and negative-matrix bound proteins. A) 
Immunoblot analysis. Each sample was examined by immunoblot analysis using anti-ADAM22-cyto antibody. B) Silver stain 
analysis. The 60-kDa specific band is indicated by an arrow. Note that the amount of IgG was greatly decreased in sample #9. C) The 
number of identified peptides for 113 proteins from the ADAM22-matrix sample (x-axis) is plotted against that from the nega-
tive-matrix sample (y-axis). These 113 proteins are listed in Table 1.  
 
Interaction between ADAMs and LGI1 protein 
The LGI1 protein is a secreted protein and 
ADAM22 is a type I transmembrane protein expressed 
on the cell surface. Therefore the interaction between 
these two molecules must occur outside the cell. To 
determine this interaction, we established a quantita-
tive cell-based ELISA system by using the mouse 
HA-tagged LGI1 protein (LGI1-HA) and the anti-HA 
monoclonal antibody. As shown in Figure 3, the 
amount of cell-bound HA signal was elevated only 
when it was co-expressed with mouse ADAM22, sug-
gesting that mouse LGI1-HA proteins bind to mouse 
ADAM22 protein in a specific manner. We next ex-
amined the binding specificity of LGI1 in relation to 
ADAM11, ADAM22 and ADAM23. As these ADAMs 
share similar sequences in the ectodomain, ADAM11 
and ADAM23 were also strong LGI1 receptor candi-
dates. To achieve an accurate normalization, we made 
assay plates in duplicate. Then we measured one plate 
for a cell-bound HA signal without permeabilization 
and examined the other plate for the total expression 
of ADAMs by FLAG detection under a permeabilized 
condition. As shown in Figure 4A, the strongest inter-
action was observed between mouse LGI1 and 
ADAM23. There was a moderate interaction for 
ADAM22 and a weaker interaction for ADAM11. Af-Int. J. Biol. Sci. 2008, 4 
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ter normalization with ADAM expression (Figures 
4B), ADAM23 exhibited a strong interaction capacity 
comparable to that of ADAM22. In contrast, ADAM11 
was less active than the others (43.3%). These results 
suggest that ADAM22 is not a sole receptor for LGI1. 
 
Interaction between ADAMs and LGI4 protein 
The LGI4 protein is another candidate ligand for 
ADAM22 receptor. This is because disruption of the 
Lgi4 gene in mice causes hypomyelination in the pe-
ripheral nerves and this phenotype is quite similar 
with that of the ADAM22 knockout mice. To address 
this hypothesis, we examined interaction between 
mouse LGI4 and mouse ADAM22 proteins by the 
cell-ELISA analysis. As shown in Figure 5, the signifi-
c a n t  a m o u n t  o f  c e l l - b o u n d  L G I 4 - H A  s i g n a l  w a s  d e -
tected only when it was co-expressed with mouse 
ADAM22, suggesting that mouse LGI4-HA proteins 
bind to mouse ADAM22 in a specific manner. We next 
examined the binding specificity of LGI4 for 
ADAM11, ADAM22 and ADAM23. Figure 6A shows 
that the strongest interaction was observed between 
mouse LGI4 and ADAM22. There was a moderate in-
teraction for ADAM11 and ADAM23. These results 
suggest that LGI4 interacts with not only ADAM22 
but also ADAM11 and ADAM23.   
0.0
0.2
0.4
0.6
0.8
1.0
1.2
LGI1-HA +
vector
LGI1-HA +
mADAM22
vector  +
mADAM22
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
 
(
4
5
0
n
m
)
 
_
_
_
 
Figure 3. Interaction of mouse LGI1-HA with mouse 
ADAM22. Cell-bound mouse LGI1-HA proteins were quanti-
fied with a cell-based ELISA system. An elevated amount of 
LGI1-HA was detected only when mouse ADAM22 was co-
transfected. Each bar represents the mean ± SEM (n = 4 wells).  
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Figure 4. Binding specificity of LGI1-HA against ADAM11, ADAM22 and ADAM23. A) Cell-bound mouse LGI1-HA proteins 
(black) and total ADAMs-FLAG (white) were quantified with a cell-based 
ELISA system. Each bar represents the mean ± SEM (n = 4 wells). B) 
Mean values of the HA signal (cell-bound mouse LGI1-HA) were nor-
malized by ADAMs (FLAG signal).  
 
 
Figure 5. Interaction of mouse LGI4-HA with mouse 
ADAM22. Cell-bound mouse LGI4-HA proteins were quanti-
fied with a cell-based ELISA system. An elevated amount of 
LGI4-HA was detected only when mouse ADAM22 was co-
transfected. Each bar represents the mean ± SEM (n = 4 wells).  
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Figure 6. Binding specificity of LGI4-HA against ADAM11, ADAM22 and ADAM23. A) Cell-bound mouse LGI4-HA proteins 
(black) and total ADAMs-FLAG (white) were quantified with a cell-based ELISA system. Each bar represents the mean ± SEM (n = 
4 wells). B) Mean values of the HA signal (cell-bound mouse LGI4-HA) were normalized by ADAMs (FLAG signal). 
 
DISCUSSION 
In a previous study, we revealed that ADAM22 is 
a cell-surface receptor predominantly expressed in 
neuronal tissues [6,7]. We then discovered several de-
fects in ADAM22 deficient mice, including i) a delay 
in body weight gain, ii) hypomyelinated peripheral 
nerves, and iii) seizures and short life spans [10]. 
These results suggest that ADAM22 is essential for the 
maintenance of proper neuronal functions in mam-
mals, however, little is known about ADAM22 at the 
molecular level. To elucidate the molecular function of 
ADAM22, we initiated a ligand-fishing study for 
ADAM22 protein. 
In this study, to obtain ADAM22-specific binder 
from mouse brain, we performed immunoprecipita-
tion using anti-ADAM22-cyto antibody and mass 
spectrometry analysis. Our GeLC-MS and emPAI 
analysis strongly suggested that LGI1 protein binds 
specifically to ADAM22. By employing a quantitative 
cell-based ELISA analysis, we demonstrated the spe-
cific interaction between LGI1 and ADAM22 on cul-
tured cells.   
The LGI1 gene was initially identified as a can-
didate tumor suppressor because the inactivation of 
the LGI1 gene is frequently observed in glioblastoma 
cell lines [15]. Later, the striking discovery was re-
ported that the mutations in the LGI1 gene cause 
autosomal-dominant partial epilepsy with auditory 
features (ADPEAF) [16]. Further studies revealed that 
LGI1 is a secreted protein and most of the mutant 
LGI1 causing ADPEAF has a secretion defect, sug-
gesting that LGI1 works as a soluble ligand for the 
unknown receptor [17]. From these data, together with 
our findings that the homozygous inactivation of the 
Adam22 gene causes seizures in mice, it seemed rea-
sonable to speculate that LGI1 inputs the signal via 
ADAM22 on the cell surface, and an epileptic seizure 
would be caused by the impairment of LGI1-ADAM22 
signaling.  
The interaction of LGI1 with ADAM22 was first 
discovered by the immunopurification of the 
post-synaptic large complex using anti-PSD-95 anti-
bodies [18]. The complex contained PSD-95, stargazin, 
ADAM22 and LGI1. Another group undertook the 
affinity purification of a Kv1 potassium channel com-
plex, and discovered that it contained PSD-95, 
ADAM22 and LGI1 [19]. As PSD-95 is known to be a 
scaffold protein for a variety of receptors or ion chan-
nels [20], there was a possibility that LGI1 interacted 
indirectly with ADAM22 through the intermediary 
PSD-95. In contrast, our GeLC-MS analysis clearly 
showed that the interaction between LGI1 and 
ADAM22 is direct. This is probably because our 
ADAM22-cyto antibody specifically interacted with 
ADAM22 cytoplasmic domain, which was not covered 
with PSD-95.   
In ADAM22-deficient mice, we observed hypo-
myelination in the peripheral nerves while CNS mye-
lin was correctly formed [10]. A very similar pheno-
type was observed in claw paw mice and the causative 
mutation was recently discovered [23]. The authors 
found that claw paw mice have a 225 base pair inser-
tion in Lgi4 gene, leading to the production of a pro-
tein that lacks exon 4. LGI4 is a member of the LGI 
family and has a sequence similarity with LGI1. Based 
on this information, another ligand-receptor pair can 
be identified, namely LGI4 and ADAM22. We exam-Int. J. Biol. Sci. 2008, 4 
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ined this hypothesis by our cell-ELISA systems and 
discovered that LGI4 strongly interacts with 
ADAM22.  
The next issue is the binding specificity of LGI1 
and LGI4 to ADAM11, ADAM22 and ADAM23, be-
cause these ADAMs share similar sequences in the 
ectodomain. By the cell-ELISA assay, we demon-
strated that LGI1 binds to ADAM23 strongly as well 
as ADAM22 and weakly binds to ADAM11, suggest-
ing that ADAM23 is another receptor for LGI1. It is 
known that ADAM23 is expressed at high levels in the 
brain [6,21], is localized on the cell surface [22], and is 
essential for normal brain function because the 
ADAM23-deficient mice exhibited ataxia, tremor and 
short life spans [11]. The knockout phenotype of 
ADAM22 and ADAM23 seems to be similar but we 
did not observe tremor in our ADAM22-deficient 
mice. As we know the mRNA expression pattern of 
ADAM23 is different from that of ADAM22 [6,10], we 
speculate that ADAM23 works as an LGI1 receptor in 
the ADAM22-negative cells.   
We also showed that LGI4 significantly binds to 
all of the three ADAMs. These results indicate that 
ADAM22 is not a sole receptor for LGI4. Despite the 
significant binding ability with LGI4 and similar ex-
pression patterns with ADAM22, we did not observe 
any myelination defects in ADAM11-deficient mice 
[8]. These results suggest that ADAM11 is dispensable 
for the proper myelination step. Since ADAM11 has a 
very short cytoplasmic domain comparing to 
ADAM22, ADAM11 may work as a supportive role or 
a negative regulator. Since there has been no report 
about the myelin status of the ADAM23-deficient 
mice, the importance of ADAM23 in the peripheral 
nerve myelination is yet to be determined. 
In summary, our results indicate that LGI1 and 
LGI4 interact with ADAM22 and related ADAMs, 
ADAM11 and ADAM23. The interaction between 
LGIs and ADAMs is not a simple one to one relation-
ship and is more complicated than we expected. To 
understand the physiological roles of LGI-ADAM 
system, examinations of the cell-type specific expres-
sion and cell-type specific transcript variants of each 
gene would be essential.   
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